US 11235044
Cancer vaccines targeting MUC16 and uses thereof
granted A61KA61K2039/53A61K2039/54
Quick answer
US patent 11235044 (Cancer vaccines targeting MUC16 and uses thereof) held by Inovio Pharmaceuticals, Inc. expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Inovio Pharmaceuticals, Inc.
- Grant date
- Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K2039/53, A61K2039/54, A61K2039/572, A61K39/00117